Prevalence and Healthcare Resource Utilization Trend in Lung Cancer, Colorectal Cancer, Breast Cancer, and Prostate Cancer in Japan 2016–2024
Author(s)
Amanda Woo, PhD1, Nikoletta Sternbach, BA2, Maria Choufany, PhD3, Leila Alaoui Sosse, Masters3, Neeyor Bose, PhD1, Mark Sales, BSc4.
1Oracle Life Sciences, Singapore, Singapore, 2Oracle Life Sciences, Austin, TX, USA, 3Oracle Life Sciences, Paris, France, 4Global Director of Commercial Research Strategy, Oracle Life Sciences, Reading, United Kingdom.
1Oracle Life Sciences, Singapore, Singapore, 2Oracle Life Sciences, Austin, TX, USA, 3Oracle Life Sciences, Paris, France, 4Global Director of Commercial Research Strategy, Oracle Life Sciences, Reading, United Kingdom.
Presentation Documents
OBJECTIVES: Cancers of the lung, colon/rectum, and breast in females and prostate in males, were among the most common causes of cancer mortality in Japan. This study aims to assess the prevalence and healthcare resource utilization (HCRU) of these cancers in Japan during 2016-2024.
METHODS: Respondents aged ≥18 years were identified from the 2016 to 2024 Japan National Health and Wellness Survey (NHWS) if they had physician-diagnosis of cancer (lung, colorectal, breast in females, prostate in males). HCRU (emergency room visits, hospitalizations), 6 months preceding to the survey, was assessed.
RESULTS: Lung cancer prevalence was relatively constant across the years, ranging between 0.10% (minimum) and 0.14% (maximum). Among respondents with lung cancer, 25.3%-43.9% (minimum-maximum) received treatment. Colorectal cancer prevalence decreased from 0.92% (2016) to 0.22% (2020-2021) before increasing to 0.60% (2024), and only 9.1%-12.5% of them had treatment. The prevalence of breast and prostate cancers increased across the years, 1.98% to 2.64% and 1.13% to 1.41%, respectively, while 26.8%-34.4% of those with breast cancer and 20.8%-29.4% of those with prostate cancers had received treatment. Regardless of cancer-type, HCRU decreased drastically across the years. Respondents with lung cancer had more emergency room visits and hospitalizations than colorectal, breast, or prostate cancers.
CONCLUSIONS: The findings provide a snapshot of cancer prevalence and HCRU between 2016 and 2024 in Japan. The prevalence trends varied across different cancer types, hinting at cancer-specific disease burden in Japan. Furthermore, the substantial proportion of respondents with cancer not being on treatment for their cancer suggests gaps in cancer care, possibly around cancer diagnosis and treatment initiation. While HCRU notably decreased across the years, the higher HCRU among those with lung cancer highlights the disease-specific nature of cancer care and the need for tailored efforts to address the HCRU burden associated with different cancer types.
METHODS: Respondents aged ≥18 years were identified from the 2016 to 2024 Japan National Health and Wellness Survey (NHWS) if they had physician-diagnosis of cancer (lung, colorectal, breast in females, prostate in males). HCRU (emergency room visits, hospitalizations), 6 months preceding to the survey, was assessed.
RESULTS: Lung cancer prevalence was relatively constant across the years, ranging between 0.10% (minimum) and 0.14% (maximum). Among respondents with lung cancer, 25.3%-43.9% (minimum-maximum) received treatment. Colorectal cancer prevalence decreased from 0.92% (2016) to 0.22% (2020-2021) before increasing to 0.60% (2024), and only 9.1%-12.5% of them had treatment. The prevalence of breast and prostate cancers increased across the years, 1.98% to 2.64% and 1.13% to 1.41%, respectively, while 26.8%-34.4% of those with breast cancer and 20.8%-29.4% of those with prostate cancers had received treatment. Regardless of cancer-type, HCRU decreased drastically across the years. Respondents with lung cancer had more emergency room visits and hospitalizations than colorectal, breast, or prostate cancers.
CONCLUSIONS: The findings provide a snapshot of cancer prevalence and HCRU between 2016 and 2024 in Japan. The prevalence trends varied across different cancer types, hinting at cancer-specific disease burden in Japan. Furthermore, the substantial proportion of respondents with cancer not being on treatment for their cancer suggests gaps in cancer care, possibly around cancer diagnosis and treatment initiation. While HCRU notably decreased across the years, the higher HCRU among those with lung cancer highlights the disease-specific nature of cancer care and the need for tailored efforts to address the HCRU burden associated with different cancer types.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD144
Topic Subcategory
Reproducibility & Replicability
Disease
SDC: Oncology